Peter J. Weiden, MD

home / authors / peter-j-weiden-md

Articles

Clozapine REMS and Other Barriers: A Conversation With Peter J. Weiden, MD

Peter J. Weiden, MD;Heidi Anne Duerr, MPH

November 30th 2024

It's time to better support clinicians prescribing clozapine, Peter J. Weiden, MD, shared in an interview.

Peter J. Weiden, MD, Discusses Clozapine REMS Challenges and Advisory Committees' Recommendations

Peter J. Weiden, MD;Heidi Anne Duerr, MPH

November 27th 2024

What does the clozapine REMS recommendations from the FDA Advisory Committees mean for clinical care?

Reframing Approaches to Schizophrenia

Peter J. Weiden, MD

July 2nd 2024

The history of new treatments coming to schizophrenia should serve as a warning...

Peter J. Weiden, MD, sat down with Psychiatric Times’ Editor-in-Chief at the 2024 Annual Meeting. Here’s Part 2 of their conversation.

Long-Acting Injectable vs Oral Antipsychotics: Part 2 of a Conversation With Peter J. Weiden, MD

Peter J. Weiden, MD;John J. Miller, MD

May 8th 2024

Peter J. Weiden, MD, sat down with Psychiatric Times’ Editor-in-Chief at the 2024 Annual Meeting. Here’s Part 2 of their conversation.

Peter J. Weiden, MD, sat down with Psychiatric Times’ Editor-in-Chief at the 2024 Annual Meeting. Here’s Part 1 of their conversation.

Long-Acting Injectables: Part 1 of a Conversation With Peter J. Weiden, MD

Peter J. Weiden, MD;John J. Miller, MD

May 8th 2024

Peter J. Weiden, MD, sat down with Psychiatric Times’ Editor-in-Chief at the 2024 Annual Meeting. Here’s Part 1 of their conversation.

Interventions to Improve Adherence to Antipsychotic Medications

Dawn I. Velligan, PhD;Peter J. Weiden, MD

August 1st 2006

New ways to address medication adherence problems in patients with schizophrenia offer the hope of better treatment outcomes. Two new and promising approaches for individuals with schizophrenia are the use of environmental supports and cognitive adaptation training and cognitive-behavioral therapy.